75,427 Shares in Immatics N.V. $IMTX Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new position in Immatics N.V. (NASDAQ:IMTX) during the first quarter, Holdings Channel reports. The firm bought 75,427 shares of the company’s stock, valued at approximately $742,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in Immatics during the 4th quarter valued at approximately $2,189,000. Baker BROS. Advisors LP raised its holdings in shares of Immatics by 18.9% during the 3rd quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company’s stock worth $103,042,000 after acquiring an additional 1,925,193 shares in the last quarter. Sofinnova Investments Inc. raised its holdings in shares of Immatics by 54.2% during the 4th quarter. Sofinnova Investments Inc. now owns 3,435,542 shares of the company’s stock worth $36,073,000 after acquiring an additional 1,207,705 shares in the last quarter. Monashee Investment Management LLC bought a new position in shares of Immatics during the 4th quarter valued at approximately $1,684,000. Finally, UBS Group AG boosted its position in shares of Immatics by 61.3% during the 4th quarter. UBS Group AG now owns 563,463 shares of the company’s stock valued at $5,916,000 after acquiring an additional 214,084 shares during the last quarter. 64.41% of the stock is owned by institutional investors.

Immatics Price Performance

NASDAQ:IMTX opened at $9.68 on Monday. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -4.86 and a beta of 1.32. The business has a 50 day simple moving average of $10.34 and a 200-day simple moving average of $10.17. Immatics N.V. has a 1 year low of $5.05 and a 1 year high of $12.41.

Immatics (NASDAQ:IMTX) last released its earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.08). Immatics had a negative net margin of 572.35% and a negative return on equity of 47.36%. The company had revenue of $8.81 million for the quarter, compared to the consensus estimate of $9.79 million. As a group, analysts expect that Immatics N.V. will post -1.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on IMTX. Weiss Ratings cut shares of Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd. Jefferies Financial Group began coverage on shares of Immatics in a research report on Monday, March 16th. They set a “buy” rating and a $18.00 price objective for the company. TD Cowen initiated coverage on shares of Immatics in a research note on Tuesday, April 28th. They issued a “buy” rating for the company. Wall Street Zen cut shares of Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Finally, Chardan Capital restated a “buy” rating and issued a $25.00 target price on shares of Immatics in a report on Tuesday, May 19th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Immatics currently has a consensus rating of “Moderate Buy” and an average price target of $20.80.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.